The effect of CO2 laser microneedling in the treatment of macular amyloidosis patients

Comparison of the efficacy of microneedling with factional CO2 laser in treatment of patients with macular amyloidosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120524009844N13

Enrollment

Registered

2025-06-20

Start date

2025-07-23

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular amyloidosis. Amyloidosis

Interventions

Intervention 1: Intervention group: Microneedling treatment: Patients underwent microneedling with a Dermapen device (depth 0.25 to 0.5 mm, two passes) in a part of the lesion in three monthly session

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Informed consent to participate in the study Age over 18 Patients who have not used any treatment in the last month. Patients who voluntarily discontinue all their treatment for up to one month. Then enter the study.

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Patients under 18 years of age Patients with coagulation problems Patients with infected patchesPatients prone to keloid scars or hypertrophic scars

Design outcomes

Primary

Measure	Time frame
Response to treatment. Timepoint: First month, second month, third month. Method of measurement: VAS scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Amirnia

Tabriz University of Medical Sciences

mehamir46@gmail.com+98 41 3549 8236

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026